organic heterocyclic compound vemurafenib 0 489.07255 489.931 pubmed:36612138 pubmed:33595357 chebi_ontology N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide wikipedia.en:Vemurafenib pubmed:22083257 pubmed:36977328 pubmed:37459870 pubmed:22028422 RO-51-85426 CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2cnc3ncc(-c4ccc(Cl)cc4)cc23)c1F drugcentral:4185 RO 5185426 GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib pubmed:21639808 pubmed:37459873 pubmed:37216396 pubmed:37021539 PLX-4032 patent:WO2010114928 pubmed:22037033 pubmed:36855200 kegg.drug:D09996 pubmed:23866896 pubmed:36765875 RG-7204 RG7204 vemurafenibum RO5185426 pubmed:21609436 PLX4032 InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28) A pyrrolopyridine that is 1<em>H</em>-pyrrolo[2,3-<em>b</em>]pyridine which is substituted at position 5 by a <em>p</em>-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases. C23H18ClF2N3O3S pubmed:36431901 N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide pdb-ccd:032 CHEBI:194457 pubmed:36906728 pubmed:36396045 drugbank:DB08881 PLX 4032 pubmed:29999925 pubmed:37325052 cas:918504-65-1 pubmed:37309702 pubmed:36598578 pubmed:22180495 pubmed:37106808 pubmed:37446932 Zelboraf RG 7204 reaxys:12833468 pubmed:34433660 pubmed:37419396 pubmed:37456058 CHEBI:63637 pubmed:37436162 Ro 51-85426 lincs.smallmolecule:LSM-1068 RO-5185426 pubmed:36713531 pubmed:35740068 pubmed:37215493